Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DermacinRx is a specialty pharmaceutical brand owned by PureTek Corporation that focuses on the development and commercialization of topical therapies for pain management and dermatology. The company's product portfolio includes a variety of prescription and over-the-counter formulations, such as lidocaine-based patches and gels, corticosteroid creams, and specialized skin repair complexes. DermacinRx is particularly known for its therapeutic kits that combine active pharmaceutical ingredients with supplemental skin care products to enhance patient outcomes and compliance. Based in California, the brand leverages PureTek's manufacturing capabilities to distribute its products through major retail pharmacies and healthcare providers across the United States. As a commercial-stage entity, DermacinRx provides cost-effective alternatives for treating conditions like postherpetic neuralgia, chronic dermatitis, and localized pain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DermacinRx.